Literature DB >> 10807884

Neuromuscular function of the human lower oesophageal sphincter in reflux disease and Barrett's oesophagus.

S D Smid1, L A Blackshaw.   

Abstract

BACKGROUND: Columnar lined (Barrett's) oesophagus is often considered a sequel to chronic severe reflux disease. Aberrant lower oesophageal sphincter (LOS) motility associated with Barrett's oesophagus includes reduced basal LOS pressures. The aim of this study was to characterise neuromuscular function of the LOS in normal (squamous cell carcinoma (SCC) with uninvolved LOS) and reflux affected (Barrett's) oesophagus in vitro.
METHODS: Strips of LOS muscle were prepared at biopsy following oesophagectomy from 16 patients with SCC and seven patients with oesophageal adenocarcinoma and Barrett's oesophagus associated with a history of reflux disease. LOS smooth muscle responses were recorded in response to electrical field stimulation (EFS), potassium chloride (KCl), DMPP, isoprenaline, capsaicin, bethanechol, and tachykinins.
RESULTS: Basal LOS tone and LOS relaxations in response to isoprenaline, EFS, and DMPP were not significantly altered in the Barrett's group. After tetrodotoxin pretreatment, responses to KCl and DMPP were significantly reduced in the SCC but not in Barrett's LOS. Maximal contraction in response to bethanechol was significantly decreased in Barrett's LOS while substance P and NK-2 receptor mediated contraction was unaltered. Capsaicin, NK-1, and NK-3 receptor agonists exerted negligible effects on LOS tone.
CONCLUSIONS: LOS muscle strips from patients with reflux associated Barrett's oesophagus exhibit a reduction in cholinergic muscle contraction while retaining similar features of basal tone, responses to tachykinins, and inhibitory muscle and neural function. Enteric inhibitory neurones in LOS muscle strips from patients with reflux associated Barrett's oesophagus display resistance to axonal sodium channel blockade. No evidence for functional NK-1 or NK-3 receptors or capsaicin sensitive axon collateral reflexes was observed in the human LOS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807884      PMCID: PMC1756439          DOI: 10.1136/gut.46.6.756

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  30 in total

1.  Acute experimental esophagitis impairs signal transduction in cat lower esophageal sphincter circular muscle.

Authors:  P Biancani; G Billett; C Hillemeier; M Nissensohn; B Y Rhim; S Szewczak; J Behar
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

2.  The actions of some beta-receptor agonists and xanthines on isolated muscle strips from the human oesophago-gastric junction.

Authors:  A Tøttrup; A Forman; G Madsen; K E Andersson
Journal:  Pharmacol Toxicol       Date:  1990-10

3.  Mechanical properties of isolated human esophageal smooth muscle.

Authors:  A Tøttrup; A Forman; N Uldbjerg; P Funch-Jensen; K E Andersson
Journal:  Am J Physiol       Date:  1990-03

4.  SNS Na+ channel expression increases in dorsal root ganglion neurons in the carrageenan inflammatory pain model.

Authors:  M Tanaka; T R Cummins; K Ishikawa; S D Dib-Hajj; J A Black; S G Waxman
Journal:  Neuroreport       Date:  1998-04-20       Impact factor: 1.837

5.  Functional foregut abnormalities in Barrett's esophagus.

Authors:  H J Stein; S Hoeft; T R DeMeester
Journal:  J Thorac Cardiovasc Surg       Date:  1993-01       Impact factor: 5.209

6.  Cholinergic responses in the cat lower esophageal sphincter show regional variation.

Authors:  H G Preiksaitis; L Tremblay; N E Diamant
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

7.  Tachykinins mediate contraction of the human lower esophageal sphincter in vitro via activation of NK2 receptors.

Authors:  O Huber; C Bertrand; N W Bunnett; C A Pellegrini; J A Nadel; P Nakazato; H T Debas; P Geppetti
Journal:  Eur J Pharmacol       Date:  1993-08-03       Impact factor: 4.432

8.  Characteristics of canine lower esophageal sphincter: a new electrophysiological tool.

Authors:  H D Allescher; I Berezin; J Jury; E E Daniel
Journal:  Am J Physiol       Date:  1988-10

9.  Muscular equivalent of the lower esophageal sphincter.

Authors:  D Liebermann-Meffert; M Allgöwer; P Schmid; A L Blum
Journal:  Gastroenterology       Date:  1979-01       Impact factor: 22.682

10.  Effect of atropine on esophageal motor function in humans.

Authors:  W J Dodds; J Dent; W J Hogan; R C Arndorfer
Journal:  Am J Physiol       Date:  1981-04
View more
  6 in total

1.  Enhanced nicotinic receptor mediated relaxations in gastroesophageal muscle fibers from Barrett's esophagus patients.

Authors:  L S Miller; A K Vegesna; A S Braverman; M F Barbe; M R Ruggieri
Journal:  Neurogastroenterol Motil       Date:  2013-12-15       Impact factor: 3.598

2.  Attenuation of acid induced oesophagitis in VR-1 deficient mice.

Authors:  K Fujino; S G de la Fuente; Y Takami; T Takahashi; C R Mantyh
Journal:  Gut       Date:  2005-08-09       Impact factor: 23.059

3.  Ca2+ signalling in interstitial cells of Cajal contributes to generation and maintenance of tone in mouse and monkey lower oesophageal sphincters.

Authors:  Bernard T Drumm; Karen I Hannigan; Ji Yeon Lee; Benjamin E Rembetski; Salah A Baker; Sang Don Koh; Caroline A Cobine; Kenton M Sanders
Journal:  J Physiol       Date:  2022-03-17       Impact factor: 6.228

Review 4.  Regulation of basal tone, relaxation and contraction of the lower oesophageal sphincter. Relevance to drug discovery for oesophageal disorders.

Authors:  R Farré; D Sifrim
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

Review 5.  Chili Peppers, Curcumins, and Prebiotics in Gastrointestinal Health and Disease.

Authors:  Tanisa Patcharatrakul; Sutep Gonlachanvit
Journal:  Curr Gastroenterol Rep       Date:  2016-04

6.  Immunohistochemical study of neuroendocrine cells at the gastric cardia mucosa.

Authors:  M Voutilainen; M Juhola; R Pitkänen; M Färkkilä; P Sipponen
Journal:  J Clin Pathol       Date:  2002-10       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.